Financials data is unavailable for this security.
View more
Year on year Jagsonpal Pharmaceuticals Ltd 's revenues fell -11.83% from 2.37bn to 2.09bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 267.21m to 224.63m, a -15.94% decrease.
Gross margin | 56.41% |
---|---|
Net profit margin | 9.67% |
Operating margin | 9.07% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Jagsonpal Pharmaceuticals Ltd increased its cash reserves by 15.44%, or 17.07m. The company earned 351.66m from its operations for a Cash Flow Margin of 16.85%. In addition the company used 245.48m on investing activities and also paid 89.11m in financing cash flows.
Cash flow per share | 8.42 |
---|---|
Price/Cash flow per share | 47.26 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -16.95%. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg) | 1.78% |
---|---|
Div growth rate (5 year) | 82.06% |
Payout ratio (TTM) | 65.13% |
EPS growth(5 years) | 25.19 |
---|---|
EPS (TTM) vs TTM 1 year ago | -36.58 |
More ▼